Bio-Rad launches QX ONE droplet digital PCR system to early access customers at AMP 2019 Annual Meeting & Expo
Baltimore – November 7, 2019 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the release of its QX ONE Droplet Digital PCR System to early access customers at the Association for Molecular Pathology (AMP) Meeting & Expo in Baltimore, November 7-11. The QX ONE System automates Bio-Rad’s Droplet Digital (ddPCR) technology into a single integrated instrument that is designed for drug development and manufacturing quality control, as well as other highly critical testing environments.
The QX ONE System automates each step of the ddPCR workflow, which includes droplet generation, amplification, and droplet reading. The system offers a five-plate capacity and continuous operation and can analyze up to 480 samples a day. The system can detect four colors simultaneously for 8-plex CNV detection, 5-plex mutation detection, and 4-plex gene expression detection.
“By fully integrating our market-leading ddPCR workflow, the QX ONE gives users sample-to-analysis results in a high-precision platform,” said Lisa Jensen-Long, Vice President of Marketing for Bio-Rad’s Digital Biology Group.
The QX ONE System is compatible with current ddPCR Supermixes, Assays, and Kits, and joins Bio-Rad’s family of Droplet Digital PCR products that includes the QXDx ddPCR System, the first FDA-cleared digital PCR platform for clinical use.
During AMP, on November 6, Bio-Rad hosted three workshops highlighting the latest advancements in ddPCR technology:
“Orthogonal Methods for Validation and Confirmation of Next Generation Sequencing Results,” a presentation by Lawrence Jennings, MD, PhD, of Lurie Children’s Hospital of Chicago
“Detection of New and Emerging Biomarkers with Clinical Relevance in NSCLC Using Blood-Based ddPCR,” presented by Gary Pestano, PhD, of Biodesix, Inc.
“QC and Your Lab,” presented by Duane Newton, PhD, D(ABMM), FIDSA, of the University of Michigan Health System
The QX ONE System is sold out for early access this year. Additional shipments are currently being scheduled for 2020. To schedule a time to view our new QX ONE instrument, please visit booth #2531 or email [email protected]
BIO-RAD, DDPCR, and DROPLET DIGITAL PCR are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.